Corcept Therapeutics | CORT - Assets


Corcept Therapeutics reported $836.65M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Alaunos Therapeutics USD 3.72M 1.01M Sep/2025
ANI Pharmaceuticals USD 1.44B 32.22M Dec/2025
Ardelyx USD 501.6M 15.43M Dec/2025
Assertio Holdings USD 319.77M 46M Sep/2025
Aurora Cannabis CAD 775.29M 18.43M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Canopy Growth CAD 1.11B 36.35M Dec/2025
Corcept Therapeutics USD 836.65M 13.04M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Lexicon Pharmaceuticals USD 184.99M 20.94M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.26B 32.66M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Supernus Pharmaceuticals USD 1.45B 32.89M Dec/2025
TG Therapeutics USD 1.06B 38.23M Dec/2025